RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
KIR/HLA 基因型与慢性乙型肝炎患者肝硬化、肝细胞癌及 NUC 停药的相关性分析
英文原题：Association analysis of KIR/HLA genotype with liver cirrhosis, hepatocellular carcinoma, and NUC freedom in chronic hepatitis B patients.
查看英文原题
Association analysis of KIR/HLA genotype with liver cirrhosis, hepatocellular carcinoma, and NUC freedom in chronic hepatitis B patients.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
NK 细胞通过杀伤细胞免疫球蛋白样受体（KIR）与人类白细胞抗原（HLA）I类配体的结合而受到调控。本研究探讨了KIR/HLA配对与乙型肝炎病毒（HBV）感染中进展为肝硬化、肝细胞癌（HCC）发生以及核苷（酸）类似物（NUC）治疗停药之间的关联。对280例日本HBV患者进行了KIR、HLA-Bw和HLA-C基因分型以进行临床比较。在肝硬化发生方面未检测到KIR/HLA配对的显著关联。HCC患者（n = 39）的KIR2DS3阳性率显著高于非HCC患者（n = 241）[30.8% vs. 14.9%，比值比（OR）2.53，P = 0.015]。NUC停药组（n = 20）的KIR3DL1/HLA-Bw4配对率显著低于NUC继续治疗组（n = 114）（25.0% vs. 52.6%，OR 0.30，P = 0.042）。
总之，本研究表明KIR/HLA与HBV患者的HCC发生（KIR2DS3）和NUC治疗停药（KIR3DL1/HLA-Bw4）存在显著关联，尽管病例数不足以满足统计学要求。需要更大规模的多中心分析来阐明KIR/HLA配对是否在HBV患者状态中发挥作用。
展开英文摘要原文
Natural killer cells are modulated through the binding of killer cell immunoglobulin-like receptors (KIRs) with human leukocyte antigen (HLA) class I ligands.
This study investigated the association of KIR/HLA pairs with progression to liver cirrhosis, hepatocellular carcinoma (HCC) development, and nucleot(s)ide (NUC) treatment freedom in hepatitis B virus (HBV) infection. KIR, HLA-Bw, and HLA-C were genotyped in 280 Japanese HBV patients for clinical comparisons. No significant associations of KIR/HLA pairs were detected in terms of liver cirrhosis development.
The KIR2DS3 positive rate was significantly higher in patients with HCC (n = 39) than in those without (n = 241) [30. 8% vs. 14. 9%, odds ratio (OR) 2. 53, P = 0. 015]. The KIR3DL1/HLA-Bw4 pair rate was significantly lower in the NUC freedom group (n = 20) than in the NUC continue group (n = 114) (25. 0% vs. 52. 6%, OR 0. 30, P = 0. 042).
In conclusion, this study indicated remarkable associations of KIR/HLA with HCC development (KIR2DS3) and freedom from NUC therapy (KIR3DL1/HLA-Bw4) in HBV patients, although the number of cases was insufficient for statistical purposes. Additional multi-center analyses of larger groups are needed to clarify whether KIR/HLA pairs play a role in HBV patient status.
论文信息
- 作者
- Joshita S、Ota M、Kobayashi H、Wakabayashi SI、Yamashita Y、Sugiura A、Yamazaki T、Tanaka E
- 单位
- Division of Gastroenterology and Hepatology, Department of Medicine, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano, 390-8621, Japan. joshita@shinshu-u.ac.jp.Japan
- 文献类型
- 非美国政府资助研究
- 期刊
- Scientific reports2021 Nov 2
- 原文标识
- PubMed 34728722 · DOI 10.1038/s41598-021-01014-x
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →